Print Page  Close Window
Investor Overview

NASDAQ | PDII (Common Stock)

$2.04

 0.15 (0.00%)

Volume19,667

Aug 27, 2015  3:58 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Company Overview

PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital communication services and integrated multichannel message delivery. For more information about PDI, Inc. or Interpace Diagnostics, please visit http://www.pdiinc.com and www.interpacediagnostics.com

Webcasts

August 13, 2015 4:30 p.m. ET

Events and Presentations

Primary IR Contact

Doug Sherk
EVC Group

Phone: (415) 652-9100

Email: dsherk@evcgroup.com